Kawasaki disease (mucocutaneous lymph node syndrome) mostly strikes babies and children under the age of five. It initially presents as a high fever that lasts for five days or more AND involves at least three of the following five symptoms: swollen glands, an angry rash, red swollen hands and feet, dry cracked lips/strawberry tongue, and bloodshot/infected eyes. In many cases, this disease causes serious and irreparable damage to the heart (usually in the form of aneurysms caused by inflammation in coronary arteries). Since Kawasaki disease symptoms are commonly seen in other general infections – including influenza and bacterial meningitis – misdiagnosis is tragically commonplace among parents and GPs.
Kawasaki disease is now recognised as the leading cause of coronary heart disease in children with effects that may be permanent for those who survive into adult life. It is the prime suspect in death by non-congenital heart failure among children and young adults. There has been a relentless increase of Kawasaki disease-related hospital admissions (from 507 in 2015/16 to 628 in 2017/18 - of which two-thirds were emergencies) in England and Wales, not to mention the undiagnosed, misdiagnosed, and adult statistics. In addition, there is some evidence of an up to a 10 per cent chance that susceptibility to Kawasaki disease is hereditary.
Although there is no evidence that sufferers are contagious during its active phase, it is possible that Kawasaki disease is airborne. If its victims survive their childhood, those worst affected and undiagnosed continue to have myocardial and vascular complications as adults. The number of Kawasaki disease victims later diagnosed has increased by 1,400 since 2009: and reported cases of Kawasaki disease probably represent just the tip of the iceberg.
Signs and symptoms include:
More information about Kawasaki Disease UK
Kawasaki Disease UK aims to help parents self-diagnose and identify the classic symptoms by day five, before the
critical phase of heart damage 11-13 days of the onset and aid recovery with treatment that prevents cardiac arrest in a young life.
To get in touch,for more information, parent guide and latest research please use the buttons below.
Dee Izmail - Founder of Kawasaki Fund
KAWASAKI FUND REG. CHARITY NO.: 1064518
KAWASAKI DISEASE UK LTD. REG. NO.: 11375141
Global Commission progresses technology health pilots to accelerate time to diagnosis for children with a rare disease
The long road to diagnosis presents one of the greatest challenges affecting the health, survival, well-being and the very identity of people affected by a rare disease and their families. 72% of rare diseases are genetic and 70% of those genetic rare diseases start in childhood. Despite advancements in medicine and technology, it can still take an average of five years or longer before a child living with a rare disease is able to receive an accurate diagnosis.
In 2018, Takeda, Microsoft and EURORDIS-Rare Diseases Europe formed the Global Commission to End the Diagnostic Odyssey for Children with a Rare Disease (“the Global Commission”) in order to bring the technology and rare disease communities together to overcome the complex barriers to a faster diagnosis. Since then, the Global Commission has been working to empower patients, families, and healthcare providers to accelerate the time to accurately diagnose a child with a rare disease by harnessing the power of technology, developing supporting policies, and driving increased awareness.
The Global Commission recently gave an update about the group’s work during the 10th Annual European Conference on Rare Diseases & Orphan Products (ECRD) virtual event, outlining its progress and path forward to accelerate the time to diagnosis. During the session, speakers including Global Commission Co-Chairs Wolfram Nothaft, M.D., Chief Medical Officer at Takeda, Gregory Moore, M.D., PhD., Corporate Vice President at Microsoft Health and Yann Le Cam, Chief Executive Officer at EURORDIS, who shared the Global Commission’s vision and goals, plans for an upcoming patient empowerment campaign and updates about innovative technology health pilots the group has been advancing. Listed below are a few key updates:
Since the launch of the Global Commission’s Year-One Report outlining actionable recommendations to end the diagnostic odyssey, the group has been supporting Foundation 29 in their development and testing of a digital platform called Dx29. The tool uses artificial intelligence to support frontline providers by linking disparate symptoms and expediting patient diagnosis. Test cases show that Dx29 has helped lead to a correct diagnosis 79% of the time.
Now more than ever, providers are looking for innovative solutions to help them care for patients in efficient, effective ways. The second pilot, launched at Children’s National Hospital in Washington, D.C., utilizes telemedicine to enable physicians and specialists to more easily collaborate through the use of virtual tools – such as facial recognition, video visits, and a triaging system. By delivering genetic assessments and counseling remotely to patients and primary care physicians, it reduces the time and cost burden of in-person consultations for the patients who often see multiple specialists before receiving a rare disease diagnosis.
A multi-channel patient empowerment and awareness campaign is being developed in close partnership with medical experts from the Global Commission and local patient organizations to increase awareness of a rare disease as a consideration among parents and/or caregivers searching for a diagnosis for their child. By leveraging multiple digital channels, the campaign drives effective conversations between parents and HCPs, and it ensures parents are reached in the right way, with the right message, at the right time.
The Global Commission recognises that there have been many impactful initiatives and technologies introduced in recent years that can help to speed the diagnostic timeline for rare disease patients, and plans to collaborate with other key players.
Yann Le Cam, Global Commission co-chair, commented “We benefit from the expertise of the Commission members and our collective track record of successful collaboration with multi-stakeholder partners to bring solutions to people living with a rare disease. Over the next five years, we aim to foster global collaboration and build on critical work underway to achieve greater impact in speeding up time to diagnosis. We plan to partner with other key rare disease organisations and leaders to develop new standards of practice for diagnosing rare diseases, leveraging advances in technology and genetics.”
Over the next five years, we aim to foster global collaboration and build on critical work underway to achieve greater impact in speeding up time to diagnosis
To learn more, you can view a brief video which provides an overview of the group’s progress to date and path forward to have a far-reaching impact – benefiting not only those living with a rare disease and their caregivers, but ultimately for all patients. A recording of the full ECRD session can also be found here.
As the Global Commission considers future efforts, the group would like to learn about the areas of interest and the relevant work that other parties are progressing. If you are interested in supporting the work of the Global Commission, you can complete this form.
The Global Commission will continue to take concerted action to advance its vision: A clear path to a timely, accurate diagnosis for children around the world.
The results indicated our baby had been infected with cytomegalovirus (CMV). We had never heard of CMV before. We were told that there was no way to know how our child would be impacted. The possible outcomes ranged from mild hearing loss, to cerebral palsy, to death. We were heartbroken that our child could have permanent affects from CMV. We went through the remainder of the pregnancy without a clear idea of what to expect, and it was truly terrifying. We used that time to seek out experimental treatment and to learn more about CMV.
We learned that CMV is a common virus, and most people will be infected at some point in their lives. The virus is usually harmless, but the impact can be devastating to immunocompromised individuals, as well as to babies infected before birth. Women who are infected with the virus during pregnancy can pass the virus to their unborn child, this is called congenital CMV. We learned that 1 in 200 infants are born with the virus in the United States, and 1 in 5 of those infants will have a permanent birth defect or health condition due to CMV. Ninety per cent of infants born with CMV will be asymptomatic but can develop symptoms months or years later. CMV causes approximately 400 infant deaths each year in the US. We do not screen all infants for CMV, although some states have required infants who fail their newborn hearing screening to be tested for CMV. Currently, there is no CMV vaccine. The only way to prevent CMV is through using good hygiene measures during pregnancy and while planning a pregnancy.
Only nine per cent of women have heard of CMV. At the time of my pregnancy I had been a nurse for eight years, and did not realise the impact CMV can have on pregnancy. CMV is rarely discussed, and is not a standard part of prenatal education.
Pippa, Amanda's daughter pictured above in a ballerina's dress and Pippa photographed smiling above
Today, our daughter is four years old. As many parents of children with disabilities can attest, Pippa is the light of our lives. CMV caused permanent brain damage in utero, resulting in many complications in her little life. She has diagnoses including: polymicrogyria (a condition where the brain develops many small folds), intellectual disability, developmental delay, epilepsy, hearing loss and more. She has trouble swallowing and has a feeding tube. She is non-verbal. Despite these challenges, she continues to be a happy and joyous child, and we are privileged to be her parents. We hope that her story can help educate pregnant women about the seriousness of CMV, and how it can be prevented.
I began working for the National CMV Foundation in January of this year, as the program director. My background is in public health nursing, and this work seemed like a perfect fit for me. Our foundation’s mission is to educate women of childbearing age about congenital CMV. Our vision is to eliminate congenital CMV in the United States for the next generation. We work to accomplish these goals through awareness activities and advocacy work. June is CMV Awareness Month, and our theme this year is: CMV Speaks. We want to speak out about this important cause of birth defects.
During CMV Awareness Month, I cannot help but think about all the lives that have been impacted by CMV, especially my daughter’s and my own. Pippa’s life and my life would be so different if it weren’t for this virus. Pippa should be running, jumping, and swimming. She should be telling stories about what happened at school. We must do better for future families.
Despite everything going on in the world, families affected by CMV are still here. Waiting for this virus to be discussed. Waiting for funding that is proportional to the devastation CMV causes. Waiting for a vaccine. Waiting for better treatment options. And waiting for a day when the burden of this disease is no more.
*Amniocentesis is a test you may be offered during pregnancy to check if your baby has a genetic or chromosomal condition, such as Down's syndrome, Edwards' syndrome or Patau's syndrome. It involves removing and testing a small sample of cells from amniotic fluid, the fluid that surrounds the unborn baby in the womb (uterus).
For more information about the National CMV Foundation and prevention tips please use the buttons below.
Before the INPDR was developed patients with rare diseases were often told that they may never meet anyone with the same condition – now there are some amazing advocates and networks that have helped patients and their families to connect across the World.
Patient registries were often unique to a certain treatment study and exclusive to the pharmaceutical company – the INPDR breaks that mould by bringing together vital information from patients across the World and providing equitable access to the data.
A lasting legacy
By sharing their experience of the disease, it will help to make a difference for families, the NPD community and future generations – maybe one day helping to find a cure.
We urge patients and their families living with Niemann-Pick Disease to speak to their clinicians and let them know they would like their data added to the Registry.
Their clinician can get in touch with us directly for support with the R&D process and relevant paperwork to ensure their patients can provide their informed consent. Patients and their families can also sign up themselves through our new website www.inpdr.org to share their experiences of living with the disease.
More information about Niemann-Pick Disease
Niemann-Pick Disease in all its forms is incredibly rare:
Acid Sphingomyelinase Deficiency (ASMD) includes Niemann-Pick Disease type A (NP-A) and type B (NP-B), which are caused by a lack of the enzyme acid sphingomyelinase leading to a build-up of toxic materials in the body.
Niemann-Pick Disease Type C (NP-C) is a hugely life-limiting neurodegenerative disease caused by an accumulation of lipids (fats) in the liver, brain and spleen.
We also have a hard-working team behind the scenes ready to guide you through the process of signing up, answer questions you might have and share our work with the rare disease community. You can contact them through the website or by emailing using the buttons below.
At least 1 in 1,000 babies are born with nystagmus. Many other people acquire nystagmus beyond infancy and into later life. It’s national and international Nystagmus Awareness Day on Saturday 20 June 2020. We may all be staying at home this year, but we can still mark the day and raise awareness to ensure that the 1 in 1,000 adults and children living with nystagmus enjoys a greater understanding of their condition and a better quality of life as a result. Here are just some of the ways people can get involved.
How amazing are you?
In the lead up to the big day, the charity is running its how amazing are you? campaign, sharing stories of adults and children who have achieved great things despite living with nystagmus, or maybe even because they do. These stories bring a great deal of hope and comfort to families where there is a new diagnosis of nystagmus. Anyone who has nystagmus can submit their story.
I would be absolutely delighted and very honoured to judge the Nystagmus Network competition … It has constantly amazed me since making my story public how many of us with VI are into photography.”
David Katz, photographer
Every time someone takes part in Nystagmus Awareness Day or tells someone what they’re doing and why, that’s one more person who understands what nystagmus is. Every pound raised or donated helps the Nystagmus Network support research teams across the UK to investigate this hugely complex condition, to find better diagnosis, treatments and continue to work towards prevention and cure.
| || |
About The Nystagmus Network
The arrival of a new baby in the family is a joyful occasion, but when parents find their child has albinism, this can prompt many questions and even concerns. Children with albinism are visually impaired and very sensitive to the sun meaning they need extra care.
Roselle Potts, Chair of the Albinism Fellowship
As the only charity in the UK and Republic of Ireland for people with albinism, we have around 40 years’ experience in helping mums and dads of young children with albinism.
The baby box from the Albinism Fellowship was a gratefully received addition to the support they have already given my family. Having something in my hands meant I could use the helpful advice without having to worry about sourcing the right items. It gave me ideas of the right creams and hats to use and my son loved the easy grip brightly coloured balls. Thank you so much, we love it!
About International Albinism Awareness Day*
About the Albinism Fellowship
For more information about the Albinism Fellowship, which provides help and support to children, their parents and adults with albinism in the UK and Republic of Ireland and information about the Albinism Fellowship Baby Box Scheme, or for interview and photo requests.
Please contact Roselle Potts at the Albinism Fellowship using the buttons below.
Over the last year volunteers have got involved in so many ways - at our children and family activities, at our fundraising events, in our ReCHarge cafe in Bon Accord, in our office, wrapping prizes and gifts, and, of course, stepping into our mascot, Charlie Dog, paws! Our corporate supporters have given their time too - helping us to raise vital funds and awareness.
Joan continues, “During lockdown, although our face to face activities have stopped our volunteers have been busy fundraising and offering quiet support with essential projects to allow us to continue operating. Fundraising has been incredibly challenging over the last few months and we have been blown away by the ingenuity and generosity of our supporters from individuals walking backwards to businesses who have donated a percentage of profits from online events to us. The current situation has forced us review how we best use our volunteers’ skills and experience - there are still plenty of opportunities to get involved and support us, we just need to be more creative and are always open to any ideas from our volunteers.”
I love wearing my volunteering hat for Charlie House and have been involved with Charlie House for a number of years. I have heard a number of Charlie House parents speak about how their lives have changed when their children have been born with varying degrees of additional support needs and also how their lives have changed again when they have found the support network in Charlie House.
Lynne Reid - Local volunteer
In the North-east of Scotland alone there are more than 1,600 babies, children and young people with complex disabilities and life-limiting conditions. Alongside running ongoing activities and services, Charlie House is undertaking an £8million appeal for a specialist support centre to be built on the grounds of Woodend Hospital offering families dedicated support and local respite facilities.
Rare disease community appeals to EU and member states to move into a new era of collective decision-making in health
14 May 2020, Paris - Today is the opening day of the 10th European Conference on Rare Diseases & Orphan Products. Conference organiser EURORDIS-Rare Diseases Europe and co-organiser Orphanet are appealing to the EU and member states to step up efforts to put in place common actions across EU policies that will advance the health and wellbeing of people in Europe.
As is the case for COVID-19, there is a clear twofold added value to grouping efforts at the EU level in order to tackle rare diseases. First, to improve the health outcomes of the 30 million people living with a rare disease in Europe. Secondly, to minimise the impact on, and maximise potential return for, the economy/ies of the EU and member states.
People living with a rare disease already know so well the lessons that communities around the world are now being forced to learn as a result of the COVID-19 pandemic. Coronavirus aggravates their health, social, economic vulnerabilities in both the short and long term.
We must quash this egocentric rhetoric emerging in some countries. It fragments Europe into diverging national-level decisions. We must combine our capacities and power at the European level, to ensure health, equity and solidarity for every individual citizen.
Yann Le Cam, CEO, Eurorodis
Yann Le Cam, Chief Executive Officer, EURORDIS, commented, “We must quash this egocentric rhetoric emerging in some countries. It fragments Europe into diverging national-level decisions. We must combine our capacities and power at the European level, to ensure health, equity and solidarity for every individual citizen. We appeal to national governments and the EU institutions wherever possible to increase efforts in the coming year and decade to collaborate across the board on relevant EU policies that will strengthen healthcare systems.”
He added, “There are many actions that the EU can take: Invest in research and innovation. Adopt legislations enhancing competitiveness and addressing unmet medical needs. Expand and consolidate the European Reference Networks. Create a structured EU approach to ensure sustainable access to orphan medicines and new transformative gene/ cell therapies for patients. To name but a few. A lack of EU coordination is both detrimental to the health of people living with a rare disease and has an unnecessary negative impact on the economy.”
Ana Rath, Director, Orphanet, commented, “Now more than ever, the EU has a vital role to play in improving the health of its citizens. ECRD 2020 focuses on how to build policies and services over the next decade that will improve the journey of living with a rare disease for patients and families. The conference builds on the work of the ongoing Rare2030 Foresight study, which will conclude next year with a comprehensive set of key recommendations to policy makers on how to improve rare disease policy.”
Now more than ever, the EU has a vital role to play in improving the health of its citizens. ECRD 2020 focuses on how to build policies and services over the next decade that will improve the journey of living with a rare disease for patients and families.
The resilience, courage and commitment of the people living with a rare disease, their families and their healthcare professionals will not be enough to overcome the challenges created by the pandemic. The power the EU and member states have when acting together should be used to negotiate collectively and generate investment. EU collaboration on research, health technologies, and healthcare is vital to tackle the types of health and economic challenges that know no borders.
The ECRD is recognised globally as the largest, patient-led rare disease event. Leading, inspiring and engaging all stakeholders to take action, the Conference is an unrivalled opportunity to network and exchange invaluable knowledge with all stakeholders in the rare disease community - patient representatives, policy makers, researchers, clinicians, industry representatives, payers and regulators.
ECRD 2020 takes place exclusively online 14-15 May. Discussions at the conference will go towards informing and building the future ecosystem of rare disease policies and services. For more information visit: www.rare-diseases.eu/.
EURORDIS-Rare Diseases Europe is a unique, non-profit alliance of over 900 rare disease patient organisations from 72 countries that work together to improve the lives of the 30 million people living with a rare disease in Europe.
By connecting patients, families and patient groups, as well as by bringing together all stakeholders and mobilising the rare disease community, EURORDIS strengthens the patient voice and shapes research, policies and patient services.
Orphanet is a unique resource, provide high-quality information and data on rare diseases, contributing to improving the diagnosis, care and treatment of patients with rare diseases.
Orphanet maintains the Orphanet rare disease nomenclature (ORPHAcode), essential in improving the visibility of rare diseases in health and research information systems.
Thanks to its network of 40 countries, Orphanet aims at orienting patients and doctors to the relevant expert resources, in Europe and beyond.
Rare Revolution Editor